Skip to main content
SpringerLink
Log in

Update on Bromocriptine in Parkinson’s Disease

  • Chapter
Book cover Drugs for the Treatment of Parkinson’s Disease

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 88))

Abstract

An important problem in the treatment of Parkinson’s disease (PD) is the large number of patients who, after a good response to levodopa, fail to maintain this response and become more symptomatic. Increasing disability is usually accompanied by dyskinesias and diurnal fluctuations in performance, predominantly “wearing-off” phenomena (Marsden and Parkes 1977; 1976). Occasionally, patients exhibit abrupt random fluctuations: “on-off” phenomena.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bernheimer J, Birkmayer W, Hornykiewicz O (1973) Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 20: 415–455

    Article  PubMed  CAS  Google Scholar 

  • Calne DB, Williams AC, Neophytides A (1978) Long-term treatment of parkinsonism with bromocriptine. Lancet 1: 735–738

    Article  PubMed  CAS  Google Scholar 

  • Caraceni TA, Celano I, Parati E (1977) Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson’s disease. J Neurol Neurosurg Psychiatry 40: 1142–1146

    Article  PubMed  CAS  Google Scholar 

  • Creese I, Sibley DR (1981) Receptor adaptations to centrally acting drugs. Ann Rev Pharmacol Toxicol 21: 357–391

    Article  CAS  Google Scholar 

  • Dougan D, Wade D, Mearrick P (1975) Effect of L-dopa metabolites at a dopamine receptor suggest a basis for “on-off” effect in Parkinson’s disease. Nature 254: 70–72

    Article  PubMed  CAS  Google Scholar 

  • Fahn S, Cote LJ, Snider SR (1979) The role of bromocriptine in the treatment of parkinsonism. Neurology 29: 1077–1083

    PubMed  CAS  Google Scholar 

  • Fischer PA, Przuntek H, Majer M (1984) Combined treatment of early states of Parkinson’s syndrome with bromocriptine and levodopa. Dtsch Med Wochenschr 109 (34): 1279–1283

    Article  PubMed  CAS  Google Scholar 

  • Fuxe K, Agnati LF, Kohler C (1981) Characterization of normal ans supersensitive dopamine receptors: effects of ergot drugs and neuropeptides. J Neural Transm 51: 3–37

    Article  PubMed  CAS  Google Scholar 

  • Gerlach J (1976) Effect of CB 1542 (bromo-alpha ergocryptine) on paralysis agitans compared with Madopar in a double blind crossover trial. Acta Neurol Scand 53: 189–219

    Article  PubMed  CAS  Google Scholar 

  • Glantz R, Goetz CJ, Nausieda P (1981) Effect of bromocriptine on the on-off phenomena. J Neural Transm 52: 41–47

    Article  PubMed  CAS  Google Scholar 

  • Godwin-Austen RB, Smith NJ (1977) Comparison of the effects of bromocriptine and levodopa in Parkinson’s disease. J Neurol Neurosurg Psychiatry 44: 4479–4482

    Google Scholar 

  • Goldstein M, Lew JY, Makamura S (1978) Dopaminephilic properties of ergot alkaloids. Fed Proc 37: 2202–2205

    PubMed  CAS  Google Scholar 

  • Goldstein M, Lieberman A, Meller E (1985) A possible molecular mechanism for the antiparkinsonian action of bromocriptine in combination with levodopa. Trends Pharm Sci 6: 436–437

    Article  CAS  Google Scholar 

  • Grimes JD, Hassan MN (1983) Bromocriptine in the long term management of advanced Parkinson’s disease. Can J Neurol Sci 10: 86–90

    PubMed  CAS  Google Scholar 

  • Gron U (1977) Bromocriptine versus placebo in levodopa treated patients with Parkinson’s disease. Acta Neurol Scand 56: 269–273

    Article  PubMed  CAS  Google Scholar 

  • Hoehn MM, Elton RL (1985) Is low dose bromocriptine effective in parkinsonism? Neurology 35: 199–206

    PubMed  CAS  Google Scholar 

  • Hornykiewicz O (1974) The mechanisms of action of L-dopa in Parkinson’s disease. Life Sci 15: 1249–1259

    Article  PubMed  CAS  Google Scholar 

  • Jaffe ME (1973) Clinical studies of carbidopa and L-dopa in the treatment of Parkinson’s disease. Adv Neurol 2: 161–172

    Google Scholar 

  • Jansen NH (1978) Bromocriptine in levodopa response losing parkinsonism: a double blind study. Eur Neurol 17: 92–99

    Article  PubMed  CAS  Google Scholar 

  • Kartzinel R, Teychenne P, Gillespie MM (1976) Bromocriptine and levodopa with or without carbidopa in parkinsonism. Lancet 2: 272–275

    Article  PubMed  CAS  Google Scholar 

  • Larsen TA, Newman R, Lewitt P (1984) Severty of Parkinson’s disease and the dosage of bromocriptine. Neurology 34: 795–797

    PubMed  CAS  Google Scholar 

  • Lees AJ, Stern GM (1981) Sustained bromocriptine therapy in previously untreated patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 44: 1020–1023

    Article  PubMed  CAS  Google Scholar 

  • Lees AJ, Haddad S, Shaw KM (1978) Bromocriptine in parkinsonism a long-term study. Arch Neurol 35: 503–505

    Article  PubMed  CAS  Google Scholar 

  • Lieberman AN, Goldstein M (1985) Bromocriptine in Parkinson’s disease. Pharmacol Rev 37: 217–227

    PubMed  CAS  Google Scholar 

  • Lieberman AN, Kupersmith M, Estey, Goldstein M (1976) Treatment of Parkinson’s disease with bromocriptine. N Engl J Med 295: 1400–1404

    Article  PubMed  CAS  Google Scholar 

  • Lieberman AN, Kupersmith M, Neophytides A (1982) Bromocriptine in Parkinson’s disease: report on 106 patients treated for up to 5 years. In: Goldstein M (ed) Ergot Compounds and brain function: neuroendocrine and neuropsychiatric aspects. Raven, New York, pp 45–53

    Google Scholar 

  • Markstein R (1981) Neurochemical effects of some ergot derivatives: a basis for their antiparkinson actions. J Neural Transm 51: 39–59

    Article  PubMed  CAS  Google Scholar 

  • Markstein R, Herrling PL (1978) The effect of bromocriptine on rat striatal adenylate cyclase and rat brain monoamine metabolism. J Neurochem 31: 1163–1172

    Article  PubMed  CAS  Google Scholar 

  • Marsden CD, Parkes JD (1976) “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1:292–296

    Google Scholar 

  • Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1: 345–349

    Article  PubMed  CAS  Google Scholar 

  • Melamed E, Hefti F (1983) Mechanism of action of short and long term L-dopa treatment in Parkinson’s disease: the role of surviving nigrostriatal dopaminergic neurons. Adv Neurol 40: 149–157

    Google Scholar 

  • Melamed E, Hefti F, Wurtman RJ (1980) Non-aminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol 8: 558–563

    Article  PubMed  CAS  Google Scholar 

  • Melamed E, Golbus M, Friedlander E, Rosenthal J (1983) Chronic L-dopa administration decreases striatal accumulation of dopamine from exogenous L-dopa in rats with intact nigrostriatal projections Neurology 33: 950–953

    PubMed  CAS  Google Scholar 

  • Muenter MD, Sharpless NS, Tyce GM (1977) Patterns of dystonia “IDI and DID” in response to L-dopa therapy for Parkinson’s disease. Mayo Clin Proc 52: 165–174

    Google Scholar 

  • Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson AL (1984) The “on- off” phenomenon in Parkinson’s disease. Relation to levodopa absorption in transport. N Engl J Med 310: 488

    Article  Google Scholar 

  • Parkes JD, Marsden CD, Donaldson I (1976) Bromocriptine treatment in Parkinson’s disease. J Neurol Neurosurg Psychiatry 39: 184–193

    Article  PubMed  CAS  Google Scholar 

  • Pfeiffer RF, Wilken K, Glaeske C (1985) Low dose bromocriptine therapy in Parkinson’s disease. Arch Neurol 42: 586–588

    Article  PubMed  CAS  Google Scholar 

  • Quinn N, Parkes D, Marsden CD (1984) Control of on-off phenomenon by continuous intravenous infusion of levodopa. Neurology 34: 1131–1136

    PubMed  CAS  Google Scholar 

  • Rascol A, Montastruc JL, Rascol O (1984) Should dopamine agonists be given early or late in the treatment of Parkinson’s disease. J Neurol Sci 11 [Suppl 1]: 229–238

    CAS  Google Scholar 

  • Reisine TD, Fields JZ, Yamamura HJ (1977) Neurotransmitter receptor alterations in Parkinson’s disease. Life Sci 21: 335–344

    Article  PubMed  CAS  Google Scholar 

  • Rinne UK (1985) Combined bromocriptine-levodopa therapy early in Parkinson’s disease. Neurology 35: 1196–1198

    PubMed  CAS  Google Scholar 

  • Schran HF, Bhuta SI, Schwarz HJ (1980) The pharmacokinetics of bromocriptine in man. In: Goldstein M (ed) compounds and brain function: neuroendocrine and neuropsychiatric aspects. Raven, New York, pp 125–139

    Google Scholar 

  • Schwartz R, Fuxe K, Agnati LF (1978) Effect of bromocriptine on 3H-spiroperidol binding sites in rat striatum — evidence for actions of dopamine receptors not linked to adenylate cyclase. Life Sci 23: 465–470

    Article  Google Scholar 

  • Spencer SE, Wooten GF (1984) Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation. Neurology 34: 1105–1108

    PubMed  CAS  Google Scholar 

  • Teychenne Pf, Bergsrud D, Racy A (1982) Bromocriptine: low dose therapy in parkinsonism. Neurology 32: 577–583

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. A. N. Lieberman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Neurology, UBC Health Sciences Centre Hospital, 2211 Wesbrook Mall, Vancouver, British Columbia, Canada, V6T 1W5

    Donald B. Calne Professor D.M., F.R.C.P., F.R.C.P.C. (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lieberman, A.N., Goldstein, M. (1989). Update on Bromocriptine in Parkinson’s Disease. In: Calne, D.B. (eds) Drugs for the Treatment of Parkinson’s Disease. Handbook of Experimental Pharmacology, vol 88. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73899-9_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-73899-9_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-73901-9

  • Online ISBN: 978-3-642-73899-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation